KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed ac...
This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipeline Under the terms of the agreement, Nxe...
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new ...
Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TC...
First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and l...
New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response...
MasterControl, a leading provider of quality and manufacturing software solutions for life sciences and regulated industries, has a...
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, and Covaris, a PerkinElmer company and leader in sample...
BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pne...
Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces that its new state-of –the-art ...
Dataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care. Illumina (NASDAQ: ILMN) and...
Telix Pharmaceuticals Limited announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivota...
Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patie...
FDA grants Fast Track Designation for Daretabart (hu1418K322A), recognising the significant unmet medical need in high-risk neuroblastoma and enabling ...
© 2026 Biopharma Boardroom. All Rights Reserved.
